Abstract:Aim: To investigate the enhancing effects of chitosan with or without enhancers on nasal recombinant hirudin-2 (rHV2) delivery in vitro and in vivo , and to evaluate the ciliotoxicity of these formulations. Methods: The permeation-enhancing effect of various chitosan formulations was estimated by using the permeation coefficient of fluorescein isothiocyanate recombinant hirudin-2 (FITC-rHV2) across the excited rabbit nasal epithelium in vitro . The effect was further evaluated by measuring the blood concentration level after nasal absorption of FITC-rHV2 in rats. The mucosal ciliotoxicity of different formulations was evaluated with an in situ toad palate model. Results: Chitosan at a concentration of 0.5% with or without various enhancers significantly increased the permeability coefficient (P) and relative bioavailability (Fr) of FITC-rHV2 compared with the blank control. The addition of 1% sodium dodecylsulfate, 5% Brij35, 5% Tween80, 1.5% menthol, 1% glycyrrhizic acid monoammonium salt (GAM) or 4% Azone into the 0.5% chitosan solution resulted in a further increase in absorption ( P <0.05) compared with 0.5% chitosan alone. But co-administration of chitosan with 5% hydroxyl-propyl-beta-cyclodextrin(HP-β-CD), 5%lecithin or 0.1% ethylenediamine tetraacetic acid (EDTA) was not more effective than using the 0.5% chitosan solution alone. Chitosan alone and with 5% HP-β-CD, 0.1% EDTA, 1% GAM or 5% Tween80 was relatively less ciliotoxic. Conclusion: Chitosan with or without some enhancers was able to effectively promote the nasal absorption of recombinant hirudin, while not resulting in severe mucosal ciliotoxicity. A chitosan formulation system would be a useful approach for the nasal delivery of recombinant hirudin.

Investigation on recombinant hirudin via oral route.

Pharmacodynamics and Pharmacokinetics of Recombinant Hirudin Via Four Non-Parenteral Routes

The Pharmacokinetics and Pharmacodynamics of Recombinant Hirudin-2 Nasal Spray

Hirudin: Administration Routes and Formulations

The Anticoagulant Effect of Recombinant Hirudin 2 after Orally Administrated to Rats

Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes.

Pharmacokinetic study with N-Ile1-Thr2-63-desulfato-r-hirudin in rabbits by means of bioassay

Nasal recombinant hirudin-2 delivery: absorption and its mechanism in vivo and in vitro studies.

Controlled Delivery of Recombinant Hirudin Based on Thermo-Sensitive Pluronic® F127 Hydrogel for Subcutaneous Administration: in Vitro and in Vivo Characterization

Experimental Studies on in Vivo Anticoagulant Activity of Recombinant Hirudin in Rabbits

Degradation of Recombinant Hirudin-2 in Nasal Mucosa of Rabbits in Vitro

Expression, Purification and Characterization of the Recombinant Hirudin Variant Iii in the Bacillus Subtilis

Improving long circulation and procoagulant platelet targeting by engineering of hirudin prodrug

Molecular dynamic and pharmacological studies on protein‐engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis

Permeation-enhancing Effects of Chitosan Formulations on Recombinant Hirudin-2 by Nasal Delivery in Vitro and in Vivo.

A Novel Hirudin Derivative Characterized with Anti-Platelet Aggregations and Thrombin Inhibition.

Construction, Expression, and Characterization of Recombinant Hirudin in Escherichia Coli.

Anti-thrombotic Effect of Recombinant RGD-Hirudin in Artery Anastomosis

Efficient targeted anticoagulant with active RGD motif.

Molecular cloning of hirudin derivative cDNA gene and expression in mammalian cell

Nanoscaled polyion complex micelles for targeted delivery of recombinant hirudin to platelets based on cationic copolymer.